Live Case Forum (April 4, 2024): ACOFP 2024 Annual Convention and Scientific Seminars

The goal of this series is to provide osteopathic primary care clinicians, with evidence-based, multidisciplinary strategies to improve knowledge and competence of pain management with non-pharmacologic and non-opioid therapies and the methodology to safely integrate opioids into treatment regimens to mitigate risks of opioid use disorder while addressing current barriers to optimal management.

State the role of both prescription and illicit opioids within osteopathic care.
Discover the appropriate circumstances for prescribing full agonist opioids for chronic pain, guided by osteopathic philosophy.
Analyze case studies to identify opportunities for using Buprenorphine and Methadone in the treatment of chronic pain or Opioid Use Disorder (OUD).
Evaluate the skills in early detection of OUD by learning tools and techniques for assessment.
Assess the risk/benefit profiles of starting, stopping, or modifying opioid prescriptions for pain management.
Develop tailored treatment plans for patients with pain or OUD to include the significance of continuous management and support and incorporate a range of treatment options such as medication-assisted treatment, behavioral therapies, and support services.

There are 4 lectures contained within this Live Case Forum series, which will be released from April 2024 through November 2024.

Live Case Forum - ACOFP (April 4, 2024): ACOFP 2024 Annual Convention and Scientific Seminars
Live Case Forum 1 (June 12, 2024): Live Virtual/Webcast
Live Case Forum 2 (August 13, 2024): Live Virtual/Webcast
In-person (September 20 - 22): OMED, San Antonio, TX
Live Case Forum - ACOI (November 1, 2024): ACOI 2024 Annual Convention and Scientific Sessions

Disclosure Statements

ACOFP and ACOI are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of an ineligible company. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACOFP and ACOI require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients). Individuals in a position to control the content may include, but are not limited to, planning committee members, authors, faculty, speakers, reviewers, and activity staff. ACOFP and ACOI review all disclosed relationships to determine which are relevant and then work with the applicable contributors to mitigate the relevant financial relationships. No relevant financial relationships were identified for any individual in control of content for this specific activity series.

CME Credit and Designation Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Osteopathic Family Physicians (ACOFP) and American College of Osteopathic Internists (ACOI). ACOFP is accredited by the ACCME to provide continuing medical education for physicians. ACOFP designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity. ACOFP is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. ACOFP designates this enduring activity for a maximum of 1.5 AOA Category 1-A credits and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program.

Support Acknowledgement

The activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.

Disclaimer

ACOFP and ACOI present this information for educational purposes only. The content is provided solely by individuals who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ACOFP, ACOI, and the supporter assume no liability for the information herein.

DEA MATE Requirements

As an accredited organization named in section 1263 of CAA 2023, ACOFP and ACOI have developed this series that may satisfy all or portions of your DE

Robert Agnello, DO, FACOFP (he/him/his)

Assistant Professor of Family Medicine

Campbell University School of Osteopathic Medicine

Dr. Robert N. Agnello is an assistant professor of family medicine and osteopathic manipulative medicine at Campbell University School of Osteopathic Medicine (CUSOM). He has been adjunct faculty since CUSOM’s inception in 2013, assisting the OMM department. Dr. Agnello is board-certified in family medicine since 2001 and holds a CAQ in pain medicine since 2017. His clinical interests lie in pain management through integrative osteopathic medicine, combining various strategies. His research focuses on complementary care modalities and their impact on pain, including osteopathic manipulation, auricular acupuncture, and functional medicine. Dr. Agnello is actively involved in professional organizations such as the American College of Osteopathic Family Physicians (ACOFP), American Osteopathic Association (AOA), and American Academy of Osteopathy (AAO).

Dr. Robert N. Agnello, DO, FACOFP has no disclosures.

Dr. Kathleen M. Farrell, DO

American College of Osteopathic Family Physicians

Kathleen M. Farrell, DO, is a graduate of the Arizona College of Osteopathic Medicine. She is certified in family medicine with the American Osteopathic Board of Family Physicians and in addiction medicine with American Osteopathic Academy of Addiction Medicine. Before obtaining her osteopathic medical degree, she earned her bachelor's degree in social welfare at the University of Washington. She is currently working for the VA in the opioid safety clinic in the pain department at American Lakes in Tacoma, Washington.

She got her "XF" soon after she got out of residency and when she started a practice with a Valley Family Health Care, a federally qualified health center in New Plymouth, Idaho. While in Idaho, she founded the Idaho Osteopathic Physicians Association and started using buprenorphine to treat her patients on illicit opioids. She continued this work when she moved to Port Angeles, Washington, to work at the Jamestown Family Health Clinic in Sequim, Washington, run by the Jamestown S'kallam Tribe. She realized that buprenorphine was not only successful in treating patients on illicit opioids, but buprenorphine could be used successfully to replace full agonist opioids in patients being treated for pain.

Her interest in working with patients on opioids continued when she became the medical director for the VA clinic in Port Angeles. When the VA started a program that allowed primary care physicians to use buprenorphine for veterans on opioids, she transferred to Tacoma. A native of the Northwest, she enjoys hiking and camping. She is a member of the Sunset Rotary Club where she has worked on "Masking the Homeless," promoting blood drives and other projects that support her community. She also enjoys Argentinian tango, which has been a COVID-challenged sport.

Dr. Kathleen M. Farrell, DO has no disclosures.

Key:

Complete

Failed

Available

Locked

Acknowledgement

Agree to terms to continue.

Agree to terms to continue. I hereby acknowledge that if I attended the live version of this course, I will not attempt to claim credits for the enduring online version. Click “I agree” to be able to continue with the product.